Philip Morris
Special Note Regarding Founder's Stock
Fields
- Type
- REPT, OTHER REPORT
- Site
- R37
- Master ID
- 1000229536/9811
Related Documents:- 1000229537-9544
- 1000229545-9550 Brief Synopsis
- 1000229551-9552 Introduction
- 1000229553-9555 Brief History of Cetus Financing
- 1000229556-9557
- 1000229558-9560 Special Note to Investors
- 1000229567-9569 Board of Directors
- 1000229575-9580 Achievements of Cetus People
- 1000229581-9599 Present Cetus Activities
- 1000229600-9616 Research Plan
- 1000229617-9619 Patents
- 1000229621-9656 Debenture Purchase Agreement
- 1000229657-9661 the Cetus Story
- 1000229663-9667 Cloning Business: It's Growing Fast It's Growing Fast
- 1000229668 World Roundup
- 1000229669-9670 Latin Drive: Brazil Spends Millions to Put Alcohol in Cars and Save Oil
- 1000229671 Can US Reduce Imports with Gasoline? Some Say Yes, But Officials Are Dubious
- 1000229672-9673 Bacterial Insulin Production Hears Reality
- 1000229674 Business World
- 1000229675-9677 Who Should Play God?
- 1000229678 Schering Plough New York Analysts' Meeting December 7, 1977
- 1000229679 Indiana Standard Labels Purchase Offer Part of Move to Wider Technology Base
- 1000229680 Big Deal for Berkley Bugs
- 1000229681 Oil-Less World May Run on Bugs
- 1000229682-9685 Tinkering with Life
- 1000229686-9687 Set for Biology's New Revolution
- 1000229688 Little Black Box of Cetus
- 1000229689-9695 Industry Is Finding More Jobs for Microbes
- 1000229696-9701 Dup of Id 1000229657-9661
- 1000229702-9710 Recombinant Molecular Research at Cetus Corporation
- 1000229711-9715 New Cetus Antibiotic
- 1000229716-9720 Letter to the Shareholders
- 1000229721-9726 Letter to Shareholders
- 1000229727-9728 Letters to the Shareholders
- 1000229729-9730
- 1000229731-9734 Letter to the Shareholders
- 1000229735-9736 Letter to Shareholders
- 1000229737-9749 the Manipulation of Genes
- 1000229750-9770 Microbial Genetics and the Future of the Pharmaceutical Industry
- 1000229771-9774 Recombinant Dna: Fact and Fiction
- 1000229775-9778 Testomony of Ronald E Cape, Phd President, Cetus Corporation, Berkeley, California Before the House Subcommittee on Science, Research and Technology
- 1000229779-9797 Biosystems Poised for Growth
- 1000229798-9805 Testimony of Ronald E. Cape, Ph.D President, Cetus Corporation, Berkley, California Before the Senate Subcommittee on Science, Technology and Space
- 1000229806-9807 Statement of Ronald E. Cape, Ph.D President, Cetus Corporation, Berkeley, California Before A Special Joint Congressional Hearing in Conjunction with Oversight Hearings on Science and Technology Policy the Senate Subcommittee on Science, Technology and Space of the Commerce, Science and Transportation Committee Presiding, Senator Adlai Stevenson, III Washington, Dc
- 1000229808-9811 Statement of Ronald E. Cape, Ph.D. President, Cetus Corporation, Berkeley, California at the Annual Meeting of the American Association for the Advancement of Science Session on Recombinant Dna Public Health and Biomedical Research Policy Washington, D.C.
- Characteristic
- CONF, CONFIDENTIAL
- Litigation
- Stmn/Produced
- Request
- Stmn/R1-004
- Stmn/R1-150
- Named Person
- Alafi
- Cape
- Farley
- Glaser
- Ward
- Cape
- Area
- WAKEHAM,HELMUT/KAROL SHARPE'S OFFICE
- Named Organization
- Cetus
- Natl Distillers
- Standard Oil
- Natl Distillers
- Date Loaded
- 05 Jun 1998
- UCSF Legacy ID
- afi84e00
Document Images
Special Note Regarding Founders' Stock
of issues. Principally, these issues include the_percentage of pre- ~ '"_ r 1.
would be willing to sell at this time, the founders `considered a number
,~:; -.
The present holdings of founding common stock have not participated in
any of the substantial recent transactions in the company's stock. The
founders (principally Drs. Cape, Farley, and Glaser) may be willing, at
this time, to sell some of their founding stock to,purchasers of stock
from the company, or to other purchasers. In determining how much they
amount up to 40% of their holdings, they intend, in any event, to retain
in value manyfold during the remainder of their productive lives. For
this reason, while they are interested in considering the advantages to
Cetus, to themselves and to prospective purchaser(s) of selling any
ferred stock already sold to Standard Oil by_-the original investors (61%
of the stock tendered), the percentage of common stock sold to Standard
Oil by the second round investors (42% of the stock.tendered) and the
percentage of common stock'sold to Natiorial Distillers by the groups
associated with founders Alafi andWard who are no-longer connected with
management (close to 100% of their shares). Another significant issue
is the substantial, but clearly minority and non controlling interest in
Cetus now held by each of two--~very-Aarge companies.
- Z?
On the other hand, Drs. Cap , Farley;- and Glaser, while interested in
some immediate liquidity,'_'have`no significant assets aside from their
--investment in and commitment to'Cetus, and fully expect this to increase
no less than 60% of their holdings for the longer term.
GO t~tiL Cp
G ~ .,~
~ l.`~ t~~ ~ ,~~~.T'_
"'UlF},~j~~Y.%~idv`Y~a.I.;.C~Yie..i ..1....
i~f~ 9~l 7 Z s
r` C4. "i S " J
7 ( .'1~ J y vti{~~ .
"{Y 0
...a AJj,. . r~ f', f~ .
)1 ':t '1l ';) l.. ~
t t- a t,1 b,
i ;ti~tJ
41
0
Gk ~ i ~-Q'Q
txt ~.:. ~~l~y t n
.n 61
s lJ~ y ,
~o
Q~
?'~; `~r~~a'~P~l ,~p ~ . ~ `. ..
OJ ~ pr liy~ aJl t
0
4-`a~P
J _ '" Q'n c?, ~J
1000229563
---
